retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Vitality Medical | Big update in the weight loss world 👏 The FDA has officially approved a new higher-dose semaglutide option, increasing the maximum weekly Weight Loss Injections in Spring,

In 2024, Novo Nordisk reported a total revenue of $40.66 billion, of which $20.88 billion was attributed to its GLP-1 drugs, which accounted for 51.4% of total revenues

[5] [6] Extensive post-marketing surveillance and clinical trials have not established a causal relationship in humans using these medications

Study: Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial

In patients with type 2 diabetes mellitus, treatment with semaglutide injection 1 mg resulted in reductions in glucose in terms of absolute change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose and 30 mg/dL (22%) for mean 24-hour glucose concentration

93 Bladder cancer cells lack asparaginase, leading to dysfunction in converting Asn to Asp

Instead, they warn patients to report persistent nausea, vomiting, abdominal pain, or other severe digestive symptoms that do not go away